cephalosporin c has been researched along with Pneumonia, Bacterial in 275 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 84 (30.55) | 18.2507 |
| 2000's | 84 (30.55) | 29.6817 |
| 2010's | 89 (32.36) | 24.3611 |
| 2020's | 18 (6.55) | 2.80 |
| Authors | Studies |
|---|---|
| Soriano, A | 1 |
| Basu, S; Bruno, CJ; De Anda, C; Feng, HP; Gao, W; Huntington, JA; Jensen, E; Kollef, MH; Rhee, EG; Shorr, AF; Yu, B; Zhang, Z | 1 |
| Chodick, G; Henig, O; Neuberger, A; Reiner-Benaim, A | 1 |
| Bruno, CJ; Butterton, JR; Gates, D; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Motyl, M; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Bassetti, M; Bruno, CJ; Castanheira, M; Huntington, JA; Jensen, EH; Johnson, MG; Motyl, M; Paterson, DL; Wolf, DJ; Yu, B | 1 |
| Bruno, CJ; De Anda, C; Feng, HP; Fiedler-Kelly, J; Gao, W; Patel, YT; Rhee, EG; Zhang, Z | 1 |
| Anda, C; Bruno, CJ; Feng, HP; Fiedler-Kelly, J; Gao, W; Johnson, MG; Patel, YT; Rhee, EG; Zhang, Z | 1 |
| Bruno, CJ; Huntington, JA; Jensen, EH; Kollef, MH; Martin-Loeches, I; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Abdelraouf, K; Kidd, JM; Nicolau, DP | 1 |
| Antonelli, A; Arena, F; Colavecchio, OL; Conte, V; Coppi, M; Di Pilato, V; Giani, T; Rossolini, GM; Santerre Henriksen, A | 1 |
| Carvalhaes, CG; Castanheira, M; Flamm, RK; Sader, HS | 1 |
| Ito, M; Kimura, T; Onozawa, S | 1 |
| Bisanti, A; Diaz, E; Martin-Loeches, I; Rodriguez, A | 1 |
| Basso, B; Crapis, M; Della Siega, P; Garlatti, E; Pontoni, E; Rosa, R; Tonizzo, M; Venturini, S | 1 |
| Ariyasu, M; Bassetti, M; Doi, Y; Echols, R; Ferrer, R; Lodise, TP; Matsunaga, Y; Naas, T; Nagata, TD; Niki, Y; Paterson, DL; Portsmouth, S; Torre-Cisneros, J; Toyoizumi, K; Wunderink, RG | 1 |
| Ariyasu, M; Clevenbergh, P; Echols, R; Kaye, KS; Kollef, M; Matsunaga, Y; Menon, A; Nagata, TD; Pogue, JM; Shorr, AF; Timsit, JF; Wunderink, RG; Zeitlinger, M | 1 |
| Bosheva, M; Gujabidze, R; Hamed, KA; Károly, É; Nemeth, A; Saulay, M; Smart, JI | 1 |
| Engelhardt, M; Gao, L; Hamed, K; Huang, H; Saulay, M | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wolf, DJ; Wunderink, RG; Yu, B | 1 |
| Eckburg, PB; File, TM; Friedland, HD; Llorens, L; Talbot, GH | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Dai, C; Hao, Z; Li, Y; Qu, S; Zhao, L; Zhu, J | 1 |
| Alessa, MA; Alhokail, M; Alhossan, A; Alkholief, MA; Almangour, TA; Tabb, DE | 1 |
| Bielicki, J; Fuchs, A; Mathur, S; Sharland, M; Van Den Anker, J | 1 |
| Batard, E; Caruana, E; Chapelet, G; Goffinet, N; Javaudin, F; Kervagoret, E; Le Bastard, Q; Montassier, E | 1 |
| Almirante, B; Burgos, J; Falcó, V | 1 |
| Aliberti, S; Blasi, F; Di Pasquale, M; Gramegna, A; Mantero, M; Saderi, L; Sotgiu, G; Trogu, F | 1 |
| Artioli, S; Bassetti, M; Capone, A; Carannante, N; Castaldo, N; Cattelan, A; Cipriani, L; Coletto, D; Digaetano, M; Grossi, P; Losito, AR; Mastroianni, CM; Menichetti, F; Mussini, C; Nicolè, S; Peghin, M; Righi, E; Russo, A; Tascini, C; Tumbarello, M; Vena, A | 1 |
| Berild, AG; Berild, D; Erichsen, D | 1 |
| Alemkere, G; Engidawork, E; Tenna, A | 1 |
| Dai, C; Hao, Z; Huang, T; Qu, S; Tang, Q; Wang, H; Yang, F; Zhang, Y | 1 |
| Bodmann, KF | 1 |
| Barberán, J; Llinares, P; Mensa, J | 1 |
| Cillóniz, C; Dominedò, C; Garcia-Vidal, C; Torres, A | 1 |
| Barberán, J | 1 |
| Grau, S | 1 |
| Mouton, JW; Muller, AE; Punt, N; Schmitt-Hoffmann, AH | 1 |
| Lagacé-Wiens, PR; Rubinstein, E | 1 |
| Cook, PP; Frenkel, A; Rimawi, RH | 1 |
| Ambrose, PG; Bhavnani, SM; Forrest, A; Khariton, T; Reynolds, DK; Riccobene, T; Rubino, CM; Van Wart, SA | 1 |
| Bousquet-Mélou, A; Ferran, AA; Henri, J; Laurentie, M; Perrin-Guyomard, A; Rolland, JG; Toutain, PL; Vasseur, MV | 1 |
| Barber, KE; Barr, VO; Casapao, AM; Davis, SL; Goff, DA; Kaye, KS; Klinker, KP; Molloy, LM; Mynatt, RP; Pogue, JM; Rybak, MJ | 1 |
| Blasi, F; Braido, F; Di Marco, F; Santus, P; Scichilone, N | 1 |
| Eckburg, PB; Friedland, HD; Jandourek, A; Llorens, L; Smith, A; Thye, DA | 1 |
| Conaway, M; Hendley, JO; Kelly, R; Willson, DF | 1 |
| Cole, P; David Friedland, H; Evans, J; Jandourek, A; Ramani, A; Smith, A; Udeani, G | 1 |
| Calbo, E; Zaragoza, R | 1 |
| Awad, SS; Chuang, YC; Engelhardt, M; Marjanek, Z; Pareigis, AJ; Reis, G; Rodriguez, AH; Sánchez, AS; Saulay, M; Scheeren, TW; Zhou, X | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Potel, G | 1 |
| Syed, YY | 1 |
| Cole, P; Evans, J; Friedland, HD; Udeani, G | 1 |
| Sinipal'nikov, AI | 1 |
| Cua, E; de Salvador, FG; Pradelli, J; Risso, K; Roger, PM; Ruimy, R | 1 |
| Welte, T | 1 |
| Anzueto, AR; File, TM; Huang, X; Lodise, TP; Shorr, AF; Smith, A; Weber, DJ; Yang, M; Zhao, Q | 1 |
| Aitken, SL; Altshuler, J; Ericsson, CD; Guervil, DJ; Hirsch, EB; Ostrosky-Zeichner, LL; Tam, VH | 1 |
| Canut, A; Isla, A; Rodríguez-Gascón, A | 1 |
| Sadikot, RT; Swenson, CE | 1 |
| Cole, P; Friedland, HD; Guervil, DJ; Hassoun, A; Huang, XY; Kaye, KS | 1 |
| Batard, E; Goffinet, N; Hardouin, JB; Lecadet, N; Lepelletier, D; Montassier, E; Potel, G | 1 |
| Airapetian, N; Ammenouche, N; Dupont, H; Friggeri, A; Levrard, M; Mahjoub, Y; Mammeri, H; Marciniak, S; Tinturier, F; Zogheib, E | 1 |
| Cillóniz, C; Liapikou, A; Torres, A | 1 |
| Scheeren, TW | 1 |
| File, TM; Friedland, HD; Iaconis, JP; Llorens, L; Melnick, D; Sun, F; Taboada, M; Wilson, D; Zhong, NS | 1 |
| Ghebremedhin, B; Rasche, K; Yayan, J | 1 |
| Blumer, JL; Bradley, JS; Cannavino, C; Friedland, HD; Ghonghadze, T; Jandourek, A; O'Neal, T | 1 |
| Bradley, JS; Cannavino, CR; Friedland, HD; Jandourek, A; Kaplan, SL; Korczowski, B; Nemeth, A; O'Neal, T | 1 |
| Bradley, JS; Carrothers, TJ; Das, S; Jandourek, A; Khariton, T; Knebel, W; Li, J; Riccobene, TA | 1 |
| Cies, JJ; Kuti, JL; Monogue, ML; Muhlebach, M; Nicolau, DP; Pettit, RS | 1 |
| Badal, RE; Biedenbach, DJ; Giao, PT; Hung Van, P; Phuong, DM; Su Minh Tuyet, N; Thi Thanh Nga, T; Vu Trung, N | 1 |
| de la Uz, CM; Kim, JJ; Miyake, CY; Moffett, BS; Niu, MC; Valdés, SO | 1 |
| Castón, JJ; De la Torre, Á; Ruiz-Camps, I; Sorlí, ML; Torre-Cisneros, J; Torres, V | 1 |
| Abdalhamid, B; Alamoudi, S; Alshami, A; Alyousef, W; Omara, A; Yahya, R | 1 |
| Danziger, LH; Glowacki, RC; Horn, KS; Rodvold, KA | 1 |
| Abrahamian, FM; Deblieux, PM; Emerman, CL; Kollef, MH; Kupersmith, E; Leeper, KV; Paterson, DL; Shorr, AF | 1 |
| Chaudhary, M; Sehgal, R; Shrivastava, SM; Varughese, L | 1 |
| Bassetti, M; Repetto, E | 1 |
| Bratzler, DW; Ma, A; Nsa, W | 1 |
| Alifano, M; Casetta, A; Coignard, S; Dermine, H; Magdeleinat, P; Meunier, A; Rabbat, A; Regnard, JF; Roche, N; Salvi, M; Schussler, O; Strano, S | 1 |
| Stiefelhagen, P | 1 |
| Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
| Ge, Y; Janes, R; Morrissey, I | 1 |
| Marco, JA; Naranjo, OR; Rodríguez de Castro, F; Violán, JS | 1 |
| Starodubtseva, OI; Vakhrushev, IaM | 1 |
| Gómez del Valle, C; Matía, M; Pérez-Calvo, JI; Torralba, MÁ | 1 |
| Chaudhary, M; Dwivedi, VK; Shrivastava, SM; Singh, CP; Soni, A | 1 |
| Hou, J; Ledesma, KR; Prince, RA; Singh, R; Tam, VH; Yuan, Z | 1 |
| Elborn, JS; Parkins, MD | 1 |
| Cooper, C; Kim, PW; Kornegay, C; Nambiar, S; Rochester, G; Valappil, T; Wang, Y; Wu, YT | 1 |
| Critchley, I; Eckburg, PB; File, TM; Friedland, HD; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, D | 1 |
| Kanafani, ZA | 1 |
| Jain, A; Kaushik, D; Rathi, S | 1 |
| Johnson, LB; Saravolatz, LD; Stein, GE | 1 |
| Laudano, JB | 1 |
| Critchley, IA; David Friedland, H; Eckburg, PB; File, TM; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, DA | 1 |
| Critchley, IA; Eckburg, PB; File, TM; Friedland, HD; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, DA | 1 |
| Friedland, HD; Laudano, JB; Rank, DR | 1 |
| Drusano, GL | 1 |
| Farrell, DJ; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Johnson, AP; Leibovici, L | 1 |
| Chen, LF; DiMondi, VP; Drew, RH | 1 |
| Chun, BC; Eom, JS; Kim, EJ; Kim, MJ; Park, DW; Sohn, JW; Yoon, YK | 1 |
| Belavic, JM | 1 |
| Amsler, K; Arbit, D; Balis, D; File, TM; Kaul, P; Michiels, B; Nicholson, SC; Noel, GJ; Strauss, RS; Welte, T | 1 |
| Nikitin, AV | 1 |
| Chaumais, MC; Jacolot, A; Judel, C; Louchahi, K; Marchand, S; Mimoz, O; Nicolas, P; Petitjean, O | 1 |
| Casapao, AM; Levine, DP; Rybak, MJ; Steed, ME | 1 |
| Lodise, TP; Low, DE | 1 |
| File, TM; Stein, GE; Wilcox, MH | 1 |
| Amador, G; Asehnoune, K; Boutoille, D; Broquet, A; Caillon, J; Desessard, C; Jacqueline, C; Le Mabecque, V; Potel, G; Roquilly, A | 1 |
| Kang, KP; Kim, W; Lee, JY; Lee, S; Park, SK | 1 |
| DeBellis, HF; Jones, MC; Kincaid, SE | 1 |
| Beraud, G; Cadranel, J; Godet, C | 1 |
| Garrison, MW; Kawamura, NM; Wen, MM | 1 |
| Aller, SC; Chusid, MJ | 1 |
| Chen, JY; Chen, YS; Huang, CK; Lee, SS; Lin, HH; Lin, WR; Liu, YC; Tsai, HC; Wann, SR; Yen, MY | 1 |
| Balbisi, EA | 1 |
| Badaró, R; Massud, J; Mendonça, J; Molinar, F; Nascimento, LO; Seas, C; Stamboulian, D | 1 |
| Burgmann, H | 1 |
| Cai, BQ; Cai, YN; Chen, XH; Gan, CL; Gao, L; Hao, FL; He, LX; Hu, BJ; Kang, J; Kong, LF; Li, JT; Liang, DR; Liu, J; Liu, YN; Lu, FF; Wang, Q; Xiao, ZL; Xue, F; Yang, WX; Yu, BX; Yu, YS; Zheng, JC; Zheng, JP; Zhou, J | 1 |
| Banks, SM; Cui, X; Eichacker, PQ; Gerstenberger, E; Hartung, T; Karzai, W; Mehlhorn, B; Natanson, C; Reinhart, K; Straube, E | 1 |
| Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Debon, R; Duflo, F; Saux, MC | 1 |
| Bergogne-Berezin, E | 1 |
| Maier, A; Smolle-Jüttner, FM; Tomaselli, F | 1 |
| Blijlevens, N; de Pauw, B; Donnelly, P; Levenga, H; Shirango, H; Verweij, P | 1 |
| Chapman, TM; Perry, CM | 1 |
| Babalola, CP; Nicolau, DP; Nightingale, CH | 1 |
| Hashiguchi, S; Iizawa, Y; Ishikawa, T; Miyake, A; Nagai, J; Nakao, M; Okonogi, K | 1 |
| Wong-Beringer, A | 1 |
| Deng, LP; Du, YP; Jiang, XT | 1 |
| Bernabéu-Wittel, M; de Cueto, M; del Carmen Conejo, M; García, I; Jiménez-Mejías, ME; Martínez-Martínez, L; Pachón, J; Pachón-Ibáñez, ME; Pascual, A; Pichardo, C | 1 |
| Arnal, JM; Berger, P; Franceschini, B; Gainnier, M; Michel, F; Papazian, L; Sainty, JM | 1 |
| Burgess, DS; Frei, CR | 1 |
| Ansart, S; Garre, M; Le Berre, R; Lerch, C; Nicolas, X; Pennec, YL; Tandé, D | 1 |
| Conejo, C; Ibáñez-Martínez, J; Martínez-Martínez, L; Pachón, J; Pachón-Ibañez, ME; Pascual, A; Pichardo, C; Rodríguez-Martínez, JM | 1 |
| Alvarez, A; Baquero, F; Cantón, R; Cobos, N; de Gracia, J; García-Quetglas, E; Gartner, S; Honorato, J; Oliver, A; Salcedo, A | 1 |
| Epstein, BJ; Gums, JG | 1 |
| Huang, JJ; Yu, JL; Zeng, Q | 1 |
| Kuti, JL; Nicolau, DP; Sun, HK | 1 |
| Zubkov, MN | 1 |
| Iakovlev, SV; Romashov, OM | 1 |
| Magid, JH | 1 |
| Anguita-Alonso, P; Hein, MM; Patel, R; Rouse, MS; Steckelberg, JM | 1 |
| Albertí, S; Alonso, D; Borrell, N; Doménech-Sánchez, A; Gomez, C; Padilla, E; Pérez, JL | 1 |
| Koulenti, D; Rello, J | 1 |
| Andrasi, M; Bagyi, K; Bognar, L; Gaspar, A; Klekner, A; Szabo, J | 1 |
| Kohlhammer, Y; Marre, R; Raspe, H; Schäfer, T; Suttorp, N; Welte, T | 1 |
| Adeyi, B; DiNubile, MJ; Friedland, IR; Ginanni, JA; McCarroll, KA; Stratchounski, LS; Wood, CA; Woods, GL; Yakovlev, SV | 1 |
| Liu, YN; She, DY; Wang, WF | 1 |
| Bonten, MJ; Buskens, E; Hoepelman, AI; Hustinx, WM; Kaasjager, K; Kramer, MH; Lammers, JW; Oosterheert, JJ; Prins, JM; Schneider, MM; Slee, PH | 1 |
| Lipman, J; Roberts, JA; Webb, SA | 1 |
| Fraser, VJ; Fridkin, SK; Kollef, MH; Merz, LR; Warren, DK | 1 |
| Aguilar, L; Barberán, J; Coronel, P; Giménez, MJ; Gimeno, M; Granizo, JJ | 1 |
| Farkas, A; Papp, M; Tornai, I; Udvardy, M | 1 |
| Adelman, MH; Eubanks, DA; Paladino, JA; Schentag, JJ | 1 |
| Azorin, J; Destable, MD; Foulon, C; Jauréguy, F; Martinod, E; Radu, DM; Seguin, A | 1 |
| Arsura, EL; Bobba, RK; Bollu, M | 1 |
| Baĭgozina, EA; Sovalkin, VI | 1 |
| Afonso, J; Campos, S; Caramori, M; Carraro, R; Jatene, F; Pêgo-Fernandes, P; Samano, M; Strabelli, T; Teixeira, R | 1 |
| Clynes, NE | 1 |
| Banke, S; Bruno, AM; Carlsson, M; Cronberg, S; Elmrud, H; Elowsson, S; Josefsson, K; Lindholm, AC; Montelius, H; Neringer, R | 1 |
| Chirurgi, V; Farkas, SA; Greene, S; Haddow, A; Heinz, G; McCabe, R | 1 |
| Brook, I | 1 |
| Belliveau, PP; Freeman, CD; Nicolau, DP; Nightingale, CH; Quintiliani, R; Tessier, PR | 1 |
| Cluzel, R; Modaï, J; Portier, H | 1 |
| Aisa, ML; Echávarri, B; Ferrer, J; Omeñaca, M; Remacha, MA; Villuendas, C | 1 |
| Fujii, R; Fujiwara, T; Inui, T; Ishihara, T; Itoh, M; Iwai, N; Kamiya, H; Kawaoi, Y; Kawasaki, H; Kondoh, Y; Kuno, K; Meguro, H; Miyajima, Y; Nakamura, H; Nakayama, M; Niinou, K; Sakurai, M; Sato, Y; Suga, S; Sunakawa, K; Taniguchi, K; Terashima, I; Toyonaga, Y; Yokota, T; Yoshimura, K | 1 |
| Alonso, JM; Fournier, JL; Jacolot, AC; Petitjean, OJ; Ramisse, F; Scavizzi, MR; Szatanik, M | 1 |
| Baños, V; Canteras, M; Gómez, J; Muñoz, L; Nuñez, ML; Ruiz Gómez, J; Soto, MC; Valdés, M | 1 |
| Lee, SK; Ng, AW; Oh, HM | 1 |
| Chiodo, F; Coronado, O; Manfredi, R; Mastroianni, A; Nanetti, A | 1 |
| Bart, BIa; Benevskaia, VF; Kasatikova, LA; Mikhaĭlusova, MP; Romanova, MV; Solov'ev, SS; Zaseeva, OV | 1 |
| Caillon, J; Jacolot, A; Louchahi, K; Mimoz, O; Padoin, C; Petitjean, O; Samii, K; Tod, M | 1 |
| Dowell, SF; Schwartz, B | 1 |
| Apul'tsina, ID; Avdeev, SN; Chuchalin, AG; Gugutsidze, EN; Kuchkina, NV; Sokolov, AS | 1 |
| Belousov, IuB; Gudkin, AB; Izotova, GN | 1 |
| Il'ina, NI; Shul'zhenko, AE | 1 |
| Chan, CH; Chan, TH; Ho, A; Lai, CK; Leung, R | 1 |
| Bonet, A; Castro, P; de Batlle, J; El-Ebiary, M; Sirvent, JM; Torres, A | 1 |
| Ballow, CH; Forrest, A; Hyatt, JM; Luzier, AB; Schentag, JJ | 1 |
| Collins, JJ; Feris, J; Giguere, G; Hidalgo, H; Higuera, F | 1 |
| Huyghens, L; Lauwers, S; Meysman, M; Monsieur, I; Vincken, W | 1 |
| Dagrosa, EE; Facco, EB; Mendoza, F; Palombini, BC; Piovano, CF | 1 |
| Bianchi, P; Drehobl, M; Griffin, TJ; Keyserling, CH; Tack, KJ | 1 |
| Holmes, C; Schlaeffer, F; Staley, H; Van den Brande, P; Vogel, F; Vondra, V | 1 |
| Lim, TK | 1 |
| Dunbar, L; File, TM; Kohler, R; Kojak, C; Player, R; Rubin, A; Segreti, J; Williams, RR | 1 |
| Medeiros, AA | 1 |
| Fraser, V; Kollef, MH; Murphy, D; Pasque, C; Sharpless, L; Vlasnik, J | 1 |
| Konstantinova, TD; Lenkova, NI; Minaev, VI; Nonikov, VE; Ritchik, LA | 1 |
| Ben-Yehuda, A; Eid, A; Safadi, R; Sviri, S; Yossepowitch, O | 1 |
| Wolff, M | 1 |
| Konstantinova, TD; Makarova, OV; Manziuk, EN; Minaev, VI; Nonikov, VE; Ritchik, LA | 1 |
| Ausina, V; Lores, L; Morera, J; Ribas, J; Ruiz, J | 1 |
| Brière, S; Brun-Buisson, C; Petit, C; Schweich, H; Sollet, JP | 1 |
| Bailly, P; Mulin, B; Rouget, C; Talon, D; Thouverez, M; Viel, JF | 1 |
| Finch, RG; Gildon, KM; Pemberton, K | 1 |
| Alcaide, F; Carratalà, J; Fernández-Sevilla, A; Gudiol, F; Rosón, B | 1 |
| Jacolot, A; Mimoz, O; Padoin, C; Petitjean, O; Samii, K; Tod, M | 1 |
| Fachinelli, H; Kijanczuk, S; Mingrone, H; Salvarezza, CR | 1 |
| Anderson, AN; Ebrahim, O; Wessels, F | 1 |
| Rogers, TR; Wort, SJ | 1 |
| Dvoretskiĭ, LI; Iakovlev, SV; Shakhova, TV; Suvorova, MP; Vlasenko, NA | 1 |
| Dvoretskiĭ, LI; Omel'ianovskiĭ, VV | 1 |
| Arai, C; Suzuki, T | 1 |
| Sieger, B | 1 |
| Dvoretskiĭ, LI; Iakovlev, SV; Shakhova, TV; Suvorova, MP | 1 |
| Cambronero Galache, JA; Cerdá Cerdá, E; Gómez Aguinaga, MA; López Diaz, J; Núnez Reiz, A; Onoro Canaveral, JJ; Rogero Marín, S; Rubio Blasco, J; Sacristán del Castillo, JA; Sánchez García, M | 1 |
| Ferguson, JK; Hensley, MJ | 1 |
| Ategbo, S; Canis, F; Husson, MO; Trivier, D; Turck, D; Vic, P | 1 |
| Baños, V; Canteras, M; Gómez Vargas, J; Gómez, J; Muñoz, L; Ruiz Gómez, J; Sánchez, ME; Simarro, E; Soto, MC; Valdés, M | 1 |
| Léophonte, P | 1 |
| Parrish, AG | 1 |
| Badenhorst, C; Barker, J; Patrick, H | 1 |
| Norrby, SR; Petermann, W; Salewski, E; Vetter, N; Willcox, PA | 1 |
| Biedenbach, DJ; Doern, GV; Jones, RN; Marshall, SA; Pfaller, MA | 1 |
| Chang, SC; Chen, YC; Fang, CT; Hsieh, SM; Hsueh, PR; Hung, CC; Liu, CJ; Sheng, WH | 1 |
| Brase, R; Heimesaat, M; Kljucar, S; Manhold, C; Timm, J; von Pritzbuer, E; von Rolbicki, U | 1 |
| de Boisblanc, BP; Haponik, E; Karam, G; Nelson, S; Omidvari, K; Summer, W | 1 |
| Chifu, S; Ebihara, M; Fukunaga, H; Furuno, T; Genka, K; Harada, Y; Hiraoka, T; Hirota, N; Inuyama, M; Ishibashi, T; Iwanaga, T; Kisanuki, K; Kishikawa, R; Makie, T; Matsukizono, K; Matsuura, Y; Mitsuno, T; Namba, K; Oe, T; Shimazu, K; Sugiyama, M; Takamoto, M; Tsumori, Y; Tsurutani, H; Ueno, Y | 1 |
| Ono, Y; Sugiyama, H | 1 |
| Ikeda, N; Matsuyama, N; Watanabe, K | 1 |
| Perret, JL; Thibault, F; Vidal, D | 1 |
| Auregan, G; Burgel, PR; Camara, P; Hovette, P; Klotz, F; Sane, M | 1 |
| Beaucaire, G; Holzapfel, L; Le Fur, D; Léophonte, P; Martin, C; Nicolas, MH; Offenstadt, G; Péan, Y; Philippon, A; Renard, S | 1 |
| Friedman, HS; Mishra, A; Sinha, AK | 1 |
| Arroliga, AC; Fatica, C; Goldstein, LS; Gordon, SM; Hall, GS; Husni, RN; Stoller, JK | 1 |
| Boulerice, F; Campbell, DA; Dubois, J; Garber, GE; Grossman, RF; Laforge, J; Landis, SJ; McIvor, RA; Murray, G; Rivard, M; Rotstein, C; Saginur, R; Stiver, HG | 1 |
| Ortqvist, A | 1 |
| Hoshiai, M; Ishihara, T; Kanemura, H; Kitano, M; Mitsui, Y; Ohno, R; Toyonaga, Y | 1 |
| Elhelali, N; Jacolot, A; Laurent, F; Léotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K | 1 |
| Asano, Y; Iriyama, J; Ishigo, S; Minakuchi, K | 1 |
| Simmons, WP | 1 |
| Belda, A; Gonzalvo, F; Martínez-Moragón, E; Pascual, JM; Ripollés, F; Rovira, E | 1 |
| Doré, P; Fauchère, JL; Ferrand, E; Grollier, G; Hira, M; Robert, R | 1 |
| Dowell, SF | 1 |
| Banevicius, MA; Nicolau, DP; Nightingale, CH; Quintiliani, R | 1 |
| Petlak, A; Słomiński, JM; Wolska-Goszka, L | 1 |
| Banevicius, MA; Bui, KQ; Nicolau, DP; Nightingale, CH; Quintiliani, R | 1 |
| Bernier, C; Bouvard, E; Meyniel, D; Parrot, A; Saidi, F | 1 |
| Jacolot, A; Leotard, S; Louchahi, K; Mimoz, O; Nordmann, P; Padoin, C; Petitjean, O | 1 |
| Kumar, AV; Rao, NR | 1 |
| Aoki, K; Asano, S; Bessho, M; Fujita, A; Furusawa, S; Higashihara, M; Hirai, H; Hoshino, S; Hotta, T; Kitamura, K; Koike, M; Kuraishi, Y; Kurihara, I; Mizoguchi, H; Nagoshi, H; Nishimura, M; Nonaka, Y; Ohbayashi, Y; Omine, M; Oshimi, K; Ozawa, K; Suzuki, K; Takaku, F; Togawa, A; Urabe, A; Wakabayashi, Y | 1 |
| Au, T; Breen, D; Reiss-Levy, E; Schonell, M | 1 |
| Ogle, JW | 1 |
| Boulétreau, P; Mohammedi, I; Vieille, E | 1 |
| Dulisse, B; Henke, CJ; Kojak, C; Martens, LL; Parasuraman, B; Potter, L; Rittenhouse, BE; Stinnett, AA; Williams, RR | 1 |
| Domarecki, A; Godula-Stuglik, U; Mazur, B; Stojewska, M | 1 |
| Boucher, BA; Croce, MA; Fabian, TC; Hanes, SD; Herring, V; Pritchard, E; Wood, GC | 1 |
| Bagge, N; Ciofu, O; Høiby, N; Skovgaard, LT | 1 |
| Bell, T; Benenson, R; Kellogg, J; Manzella, J; Pellerin, G; Pope, D; Robertson, M | 1 |
| Bogdanov, MB; Chernen'kaia, TV | 1 |
| Carratalà, J; Dorca, J; Gudiol, F; Liñares, J; Manresa, F; Pallares, R; Rosón, B; Tubau, F | 1 |
| Dresser, LD; Niederman, MS; Paladino, JA | 1 |
| Alvarez-Lerma, F; Barcenilla, F; Insausti-Ordeñana, J; Jordá-Marcos, R; Maraví-Poma, E; Martínez-Pellús, A; Nava, J; Palomar, M; Torres-Martí, A | 1 |
| Lacy, MK; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R | 1 |
| Chang, FY; Lin, JC; Peng, MY; Yeh, KM | 1 |
| Luo, G; Luo, H; Tan, X | 1 |
| Servais, H; Tulkens, PM | 1 |
| Kobashi, Y; Matsushima, T; Okimoto, N; Soejima, R | 1 |
| Bouza, E; Cordero, E; Pachon, J; Ruiz, I | 1 |
| Alegre-Martin, J; Odenholt, I; Petermann, W; Phillips, MJ; Tack, K; Trostmann, U; Welling, L; Willcox, PA | 1 |
| Knirsch, C; Luchsinger, JA; Pablos-Méndez, A; Rabinowitz, D; Shea, S | 1 |
| Higashiyama, Y; Hirakata, Y; Kadota, JI; Kakeya, H; Kaneko, Y; Kohno, S; Kuroki, M; Miyazaki, Y; Ohi, H; Tomono, K; Yanagihara, K | 1 |
| Rahman, M; Shoma, S; Yasmin, M | 1 |
| Badolati, A; Fontán, PA; Gammella, D; Maskin, B; Spinedi, EG | 1 |
| Caballero-Lopez, J; Carides, A; Friedland, IR; Ortiz-Ruiz, G; Woods, GL | 1 |
| Burns, JL | 1 |
| Adair, CG; Byers, LM; Crowe, M; Feron, B; Gorman, SP; Jones, DS; McCarthy, GJ; Milligan, KR; Webb, HC | 1 |
| Andrieu, P; Archambaud, M; Bonnet, E; Chabanon, G; Chaminade, B; Conil, JM; Cougot, P; Decun, JF; Georges, B; Houin, G; Roche, C; Saivin, S; Samii, K; Virenque, C | 1 |
53 review(s) available for cephalosporin c and Pneumonia, Bacterial
| Article | Year |
|---|---|
Ceftaroline.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Staphylococcus aureus | 2021 |
Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Guidelines as Topic; Humans; Infant; Infant, Newborn; Pneumonia, Bacterial; World Health Organization | 2018 |
Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial | 2018 |
Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Retrospective Studies; Treatment Outcome | 2018 |
[The 2018 Update of the Recommendations of the Paul-Ehrlich-Society for Chemotherapy on the Initial Parenteral Therapy of Bacterial Diseases in Adults - What's relevant for Intensive Care?]
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Critical Care; Critical Illness; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Pneumonia, Bacterial; Practice Guidelines as Topic; Sepsis; Staphylococcal Infections | 2019 |
Ceftobiprole for the treatment of pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Administration Schedule; Humans; Pneumonia, Bacterial; Renal Insufficiency | 2019 |
Possible clinical indications of ceftobiprole.
Topics: Anti-Bacterial Agents; Bacterial Infections; Catheter-Related Infections; Cephalosporins; Cross Infection; Diabetic Foot; Fever of Unknown Origin; Humans; Inpatients; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections | 2019 |
Safety and tolerability of ceftobiprole.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Neutropenia; Pneumonia, Bacterial; Pseudomonas aeruginosa; Streptococcus pneumoniae | 2019 |
Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Cross Infection; Dose-Response Relationship, Drug; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Treatment Outcome | 2013 |
The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Disease Eradication; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive | 2014 |
Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Approval; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Prodrugs | 2014 |
[Ceftaroline: new possibilities of short-term courses of antibacterial therapy in hospitalized patients with extramural pneumonia].
Topics: Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Hospitalization; Humans; Pneumonia, Bacterial; Severity of Illness Index | 2014 |
Achromobacter respiratory infections.
Topics: Achromobacter; Age Factors; Anti-Bacterial Agents; Bronchiectasis; Cefoperazone; Cephalosporins; Community-Acquired Infections; Comorbidity; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Neoplasms; Penicillins; Piperacillin; Pneumonia, Bacterial; Respiratory Tract Infections; Risk Factors; Sex Factors; Ticarcillin; Virulence Factors | 2015 |
Ceftobiprole for the treatment of pneumonia: a European perspective.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Europe; Humans; Pneumonia, Bacterial; Treatment Outcome | 2015 |
Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Cross Infection; Drug-Related Side Effects and Adverse Reactions; Enterobacteriaceae; Enterococcus; Europe; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Staphylococcus aureus; Treatment Outcome | 2015 |
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic | 2016 |
Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Critical Illness; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Staphylococcal Infections | 2017 |
Health care-associated pneumonia: identification and initial management in the ED.
Topics: Acetamides; Age Distribution; Aged; Aged, 80 and over; Anti-Infective Agents; beta-Lactams; Cephalosporins; Cross Infection; Emergency Treatment; Ertapenem; Female; Humans; Length of Stay; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Oxazolidinones; Patient Care Team; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Practice Guidelines as Topic; Respiration, Artificial; Risk Factors; Severity of Illness Index; Tigecycline | 2008 |
[Diagnostic and therapeutic management of Gram-negative infections].
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Cross Infection; Disease Management; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Italy; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
New antimicrobial molecules and new antibiotic strategies.
Topics: Acetamides; Anti-Infective Agents; beta-Lactams; Cephalosporins; Community-Acquired Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Ertapenem; Fluoroquinolones; Humans; Ketolides; Linezolid; Lipopeptides; Oxazolidinones; Pneumonia, Bacterial; Practice Guidelines as Topic | 2009 |
Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cystic Fibrosis; Doripenem; Humans; Minocycline; Pneumonia, Bacterial; Pseudomonas aeruginosa; Staphylococcus aureus; Stenotrophomonas maltophilia; Tigecycline | 2010 |
Meta-analysis of a possible signal of increased mortality associated with cefepime use.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Child; Child, Preschool; Clinical Trials as Topic; Female; Fever of Unknown Origin; Humans; Infant; Infant, Newborn; Male; Middle Aged; Neutropenia; Pneumonia, Bacterial; Skin Diseases, Bacterial; Survival Analysis; Urinary Tract Infections; Young Adult | 2010 |
Ceftaroline: a comprehensive update.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Drug Approval; Humans; Pneumonia, Bacterial; Prodrugs; Skin Diseases, Bacterial; Soft Tissue Infections; United States | 2011 |
Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Topics: Adult; Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Rabbits; Staphylococcal Infections; Streptococcus pneumoniae | 2011 |
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Prodrugs; Skin Diseases, Bacterial; Soft Tissue Infections; United States | 2011 |
What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia?
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Community-Acquired Infections; Hospitalization; Humans; Pneumonia, Bacterial | 2011 |
[Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Skin Diseases, Bacterial | 2011 |
Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Pneumonia, Bacterial; Skin Diseases, Bacterial | 2012 |
Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Double-Blind Method; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial | 2012 |
Summary of ceftaroline fosamil clinical trial studies and clinical safety.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Humans; Pneumonia, Bacterial; Staphylococcal Skin Infections | 2012 |
Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rabbits; Staphylococcal Infections | 2012 |
Cefditoren, a new aminothiazolyl cephalosporin.
Topics: Acute Disease; Bacterial Infections; Bronchitis, Chronic; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Interactions; Humans; Maxillary Sinusitis; Pharyngitis; Pneumonia, Bacterial; Skin Diseases, Bacterial | 2002 |
Fatal hemorrhagic pneumonia caused by infection due to Kytococcus sedentarius--a pathogen or passenger?
Topics: Actinomycetales; Actinomycetales Infections; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Translocation; Cefepime; Cephalosporins; Clostridium Infections; Colistin; Cytarabine; Daunorubicin; Drug Therapy, Combination; Etoposide; Fatal Outcome; Hemoptysis; Humans; Hydroxyurea; Immunocompromised Host; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Metronidazole; Middle Aged; Neutropenia; Pneumonia, Bacterial; Superinfection; Teicoplanin; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
Topics: Cefepime; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial | 2003 |
Treating serious infections: focus on cefepime.
Topics: Cefepime; Cephalosporins; Cross Infection; Humans; Neutropenia; Pneumonia, Bacterial | 2004 |
[Bacteremia and pneumonia due to Yersinia enterocolitica serotype O:3 in an immunocompetent patient].
Topics: Aged; Bacteremia; Cephalosporins; Drug Therapy, Combination; France; Humans; Immunocompetence; Male; Pneumonia, Bacterial; Serotyping; Trimethoprim, Sulfamethoxazole Drug Combination; Yersinia enterocolitica; Yersinia Infections | 2005 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Inhalation; Injections, Intravenous; Lung Diseases; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Macrolides; Pneumonia, Bacterial; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2005 |
[Cephalosporins and community-acquired pneumonia: a choice alternative].
Topics: Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Pneumonia, Bacterial | 2005 |
[Role of cefepime in the treatment of hospital-acquired pneumonia].
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Cross Infection; Humans; Pneumonia, Bacterial | 2005 |
Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care.
Topics: Acinetobacter Infections; Administration, Inhalation; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Methicillin Resistance; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Practice Guidelines as Topic; Pseudomonas Infections; Respiration, Artificial; Vancomycin | 2006 |
Cefepime versus ceftazidime: considerations for empirical use in critically ill patients.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Resistance; Economics, Pharmaceutical; Humans; Pneumonia, Bacterial | 2007 |
The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clin
Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Administration Schedule; Haemophilus Infections; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Pneumonia, Bacterial; Respiratory Tract Infections; Streptococcus pneumoniae; Treatment Outcome | 2006 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; Bacteremia; Bacterial Infections; Cefotaxime; Cephalosporins; Ciprofloxacin; Fluoroquinolones; Gastrointestinal Hemorrhage; Humans; Infusions, Intravenous; Liver Cirrhosis; Norfloxacin; Peritonitis; Pneumonia, Bacterial; Primary Prevention; Severity of Illness Index; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2007 |
[Slowly-evolving pneumonia in a 14-year-old boy].
Topics: Adolescent; Cefuroxime; Cephalosporins; Drug Resistance, Microbial; Eikenella corrodens; Gram-Negative Bacterial Infections; Humans; Male; Pneumonia, Bacterial | 1995 |
Resistant pneumococci: protecting patients through judicious use of antibiotics.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Prescriptions; Drug Resistance, Microbial; Humans; Otitis Media; Penicillins; Pneumonia, Bacterial; Streptococcus pneumoniae | 1997 |
Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Cefotaxime; Ceftriaxone; Cefuroxime; Cephalosporins; Community-Acquired Infections; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Hospital Costs; Humans; Infant; Length of Stay; Odds Ratio; Pneumonia, Bacterial; Retrospective Studies; South Africa; Treatment Outcome | 1998 |
[Differential use of cephalosporins in treatment of upper and lower respiratory tract infections].
Topics: Administration, Oral; Age Factors; Aged; Biological Availability; Cephalosporins; Community-Acquired Infections; Cross Infection; Humans; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Respiratory Tract Infections | 1998 |
[Klebsiella pneumoniae pneumonia].
Topics: beta-Lactamases; Cephalosporins; Diagnosis, Differential; Humans; Klebsiella Infections; Klebsiella pneumoniae; Penicillin Resistance; Pneumonia, Bacterial | 1999 |
[Pseudomonas aeruginosa pneumonia].
Topics: Cefoperazone; Cephalosporins; Diagnosis, Differential; Humans; Immunocompromised Host; Penicillins; Piperacillin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 1999 |
[Pulmonary melioidosis].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Chloramphenicol; Clavulanic Acid; Diagnosis, Differential; Doxycycline; Drug Therapy, Combination; Humans; Melioidosis; Penicillins; Pneumonia, Bacterial; Radiography, Thoracic; Trimethoprim, Sulfamethoxazole Drug Combination | 1998 |
In-hospital management of adults who have community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Diagnosis, Differential; Europe; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Patient Admission; Pneumonia, Bacterial; United States | 1999 |
82 trial(s) available for cephalosporin c and Pneumonia, Bacterial
| Article | Year |
|---|---|
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Probability; Renal Insufficiency; Tazobactam; Treatment Outcome | 2021 |
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Tazobactam; Ventilators, Mechanical | 2022 |
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Retrospective Studies; Tazobactam; Ventilators, Mechanical | 2022 |
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Kidney Failure, Chronic; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Probability; Renal Dialysis; Tazobactam; Ventilators, Mechanical | 2023 |
Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Topics: Anti-Bacterial Agents; Bacteria; Cephalosporins; Hospitals; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tazobactam; Ventilators, Mechanical | 2023 |
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Monobactams; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tazobactam; Vasoconstrictor Agents; Ventilators, Mechanical | 2022 |
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Female; Humans; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Tazobactam; Treatment Outcome | 2019 |
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Sepsis; Urinary Tract Infections; Young Adult | 2021 |
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Male; Meropenem; Pneumonia, Bacterial | 2021 |
A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
Topics: Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cross Infection; Female; Hospitalization; Humans; Infant; Infusions, Intravenous; Male; Pneumonia, Bacterial; Treatment Outcome; Vancomycin | 2021 |
A
Topics: Asia, Eastern; Cephalosporins; Community-Acquired Infections; Cross Infection; Humans; Pneumonia, Bacterial | 2021 |
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Equivalence Trials as Topic; Female; Healthcare-Associated Pneumonia; Humans; Logistic Models; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Tazobactam | 2021 |
Antibiotic use practice and predictors of hospital outcome among patients with systemic bacterial infection: Identifying targets for antibiotic and health care resource stewardship.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Female; Health Resources; Humans; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Sepsis; Vancomycin | 2019 |
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Male; Middle Aged; Models, Biological; Pneumonia, Bacterial; Skin Diseases, Bacterial; Young Adult | 2013 |
Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2014 |
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
Topics: Acetamides; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cross Infection; Double-Blind Method; Drug Therapy; Female; Humans; Linezolid; Male; Middle Aged; Oxazolidinones; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2014 |
Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2015 |
A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Female; Humans; Infant; Infusions, Intravenous; Male; Pneumonia, Bacterial; Treatment Outcome; Vancomycin | 2016 |
A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Female; Hospitalization; Humans; Infant; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Prospective Studies; Staphylococcus aureus; Treatment Outcome | 2016 |
Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Lung; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Patient Safety; Penicillanic Acid; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Tazobactam | 2016 |
Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Pseudomonas Infections; Treatment Outcome | 2008 |
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2010 |
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Bacteria; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2011 |
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Bacteria; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2011 |
Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial | 2011 |
Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Europe; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Treatment Outcome; United States | 2011 |
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Disease Eradication; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Linezolid; Male; Middle Aged; Oxazolidinones; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2012 |
Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
Topics: Adolescent; Aged; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Ceftazidime; Cephalosporins; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Taiwan; Treatment Outcome; Urinary Tract Infections | 2002 |
A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Cefepime; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Peritonitis; Pneumonia, Bacterial; Prospective Studies; Sepsis; Severity of Illness Index; South America; Treatment Outcome; Urinary Tract Infections | 2002 |
[Comparative study on cefdinir and cefaclor in the treatment of patients with mild to moderate bacterial community acquired pneumonia].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cephalosporins; Community-Acquired Infections; Humans; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Single-Blind Method; Staphylococcal Infections; Streptococcal Infections | 2004 |
[Therapeutic effects of cefepime and sulbactam/cefoperazone on moderate and severe respiratory tract infection in children].
Topics: Anti-Bacterial Agents; Cefepime; Cefoperazone; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Male; Pneumonia, Bacterial; Sulbactam | 2005 |
Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Double-Blind Method; Drug Administration Schedule; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Intensive Care Units; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Skilled Nursing Facilities | 2006 |
Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Cephalosporins; Clavulanic Acid; Community-Acquired Infections; Drug Combinations; Humans; Infusions, Intravenous; Middle Aged; Pneumonia, Bacterial; Time Factors; Treatment Outcome | 2006 |
Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Ceftriaxone; Cephalosporins; Cross Infection; Double-Blind Method; Drug Administration Schedule; Drug Costs; Female; Humans; Injections, Intramuscular; Male; Nursing Homes; Pneumonia, Bacterial | 2007 |
Ampicillin plus mecillinam vs. cefotaxime/cefadroxil treatment of patients with severe pneumonia or pyelonephritis: a double-blind multicentre study evaluated by intention-to-treat analysis.
Topics: Amdinocillin; Ampicillin; Cefadroxil; Cefotaxime; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Escherichia coli Infections; Female; Fever; Humans; Male; Middle Aged; Penicillins; Pneumonia, Bacterial; Pyelonephritis | 1995 |
A new therapeutic option for the treatment of pneumonia.
Topics: Acute Disease; Aged; Canada; Cefepime; Ceftazidime; Cephalosporins; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Puerto Rico; United States | 1996 |
Serum bactericidal activity of ceftizoxime and ceftriaxone against pathogens associated with community-acquired and nosocomial pneumonias.
Topics: Adolescent; Adult; Ceftizoxime; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cross Infection; Cross-Over Studies; Female; Humans; Male; Pneumonia, Bacterial; Prospective Studies; Serum Bactericidal Test | 1996 |
[Optimum dose study of cefozopran in the pediatric field].
Topics: Bacterial Infections; Cefozopran; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Pneumonia, Bacterial | 1996 |
Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Agents; Cefuroxime; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Community-Acquired Infections; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Penicillins; Pneumonia, Bacterial; Treatment Outcome | 1996 |
[The use of the cephalosporin antibiotic Zinnat under polyclinic conditions in treating patients with bronchopulmonary infections].
Topics: Acute Disease; Adolescent; Adult; Ambulatory Care; Bronchitis; Cefuroxime; Cephalosporins; Chronic Disease; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prodrugs | 1996 |
[Treatment of patients with pneumonia, chronic obstructive bronchitis and mucoviscidosis with cefpirome].
Topics: Adolescent; Adult; Aged; Bacterial Infections; Bronchitis; Cefpirome; Cephalosporins; Chronic Disease; Cystic Fibrosis; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa; Staphylococcus; Treatment Outcome | 1996 |
[Experience using cefpirome in pneumonia].
Topics: Adult; Bacterial Infections; Bronchitis; Cefpirome; Cephalosporins; Chronic Disease; Female; Humans; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Treatment Outcome | 1996 |
[Experience using cefpirome in patients with infections of the bronchopulmonary system].
Topics: Acute Disease; Adolescent; Adult; Agammaglobulinemia; Bacterial Infections; Bronchitis; Cefpirome; Cephalosporins; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 1996 |
Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime.
Topics: Adult; Aged; Ceftazidime; Cephalosporins; Cilastatin; Community-Acquired Infections; Drug Therapy, Combination; Female; Follow-Up Studies; Hong Kong; Hospitalization; Humans; Imipenem; Injections, Intravenous; Male; Pneumonia, Bacterial; Protease Inhibitors; Survival Rate; Thienamycins | 1997 |
Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma.
Topics: Adult; Antibiotic Prophylaxis; Cefuroxime; Cephalosporins; Coma; Cross Infection; Female; Humans; Infusions, Intravenous; Male; Multivariate Analysis; Pneumonia, Bacterial; Prospective Studies; Respiration, Artificial; Risk Factors | 1997 |
Modeling the response of pneumonia to antimicrobial therapy.
Topics: Anti-Infective Agents; Cefmenoxime; Ceftazidime; Cephalosporins; Ciprofloxacin; Clinical Trials as Topic; Humans; Microbial Sensitivity Tests; Models, Biological; Pneumonia, Bacterial; Predictive Value of Tests; Regression Analysis; Treatment Outcome | 1997 |
Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cefuroxime; Cephalosporins; Child; Clavulanic Acids; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prodrugs; Prospective Studies; Treatment Outcome | 1996 |
Cefodizime once daily in the treatment of lower respiratory tract infections.
Topics: Adult; Aged; Bronchitis; Cefotaxime; Cephalosporins; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Respiratory Tract Infections | 1997 |
Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cefaclor; Cefdinir; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome; United States | 1997 |
Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia.
Topics: Administration, Oral; Cefuroxime; Cephalosporins; Community-Acquired Infections; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Prodrugs; Prospective Studies; Treatment Outcome | 1997 |
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prodrugs; Prospective Studies; Treatment Outcome | 1997 |
[Amoxycillin/potassium clavulanate in inpatients with bronchopulmonary infections].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Bronchitis; Cefotaxime; Cephalosporins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 1997 |
Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. The Cefpirome Pneumonia Study Group.
Topics: Adult; Cefpirome; Ceftazidime; Cephalosporins; Critical Care; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 1998 |
Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Consumer Product Safety; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Population; Treatment Failure; Ventilators, Mechanical | 1998 |
Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime.
Topics: Adolescent; Adult; Age Factors; Aged; Ceftazidime; Cephalosporins; Community-Acquired Infections; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Respiration, Artificial; Risk Factors; Sex Factors; Thienamycins; Treatment Outcome | 1998 |
Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cefotaxime; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Roxithromycin; Streptococcus pneumoniae | 1998 |
[Stepwise therapy of community-acquired pneumonia. Results of cefuroxime and cefuroxime axetil study].
Topics: Administration, Oral; Adolescent; Adult; Aged; Cefuroxime; Cephalosporin Resistance; Cephalosporins; Chromatography, High Pressure Liquid; Community-Acquired Infections; Drug Administration Schedule; Female; Humans; Injections, Intraperitoneal; Male; Middle Aged; Pneumonia, Bacterial; Prodrugs; Treatment Outcome | 1998 |
[Program of empirical antibacterial therapy of community-acquired pneumonia].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftibuten; Cefuroxime; Cephalosporins; Community-Acquired Infections; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Male; Middle Aged; Pefloxacin; Pneumonia, Bacterial; Roxithromycin; Spiramycin | 1998 |
Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients. A randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Bacteria; Bacterial Infections; Cause of Death; Ceftriaxone; Cephalosporins; Colony Count, Microbial; Confidence Intervals; Critical Care; Critical Illness; Digestive System; Double-Blind Method; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Health Care Costs; Humans; Incidence; Intubation, Intratracheal; Length of Stay; Male; Middle Aged; Oropharynx; Placebos; Pneumonia, Bacterial; Respiration, Artificial; Survival Rate | 1998 |
[Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
Topics: Adolescent; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Humans; Pneumonia, Bacterial; Pseudomonas Infections; Tobramycin | 1998 |
[Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Ceftriaxone; Cefuroxime; Cephalosporins; Child; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies | 1998 |
A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; International Cooperation; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome | 1998 |
Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment.
Topics: Asian People; Bacteremia; Bacterial Infections; Cefepime; Ceftazidime; Cephalosporins; Humans; Pneumonia, Bacterial; Taiwan; Urinary Tract Infections | 1998 |
Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study.
Topics: Adult; Anti-Infective Agents; APACHE; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Drug Therapy, Combination; Gentamicins; Humans; Intensive Care Units; Pneumonia, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Superinfection | 1998 |
Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cefaclor; Cefamandole; Cephalosporins; Community-Acquired Infections; Female; Health Care Costs; Hospitalization; Humans; Injections, Intravenous; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 1998 |
[Clinical efficacy of sulbactam/ampicillin in comparison with cefotiam in the treatment of elderly patients with pneumonia].
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Ampicillin; Aspartate Aminotransferases; Cefotiam; Cephalosporins; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Pneumonia, Bacterial; Sulbactam; Treatment Outcome | 1998 |
[Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study].
Topics: Amikacin; Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Female; France; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Middle Aged; Pneumonia, Bacterial; Respiration, Artificial; Survival Rate | 1999 |
Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin.
Topics: Aged; Aged, 80 and over; Cefepime; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Male; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 1999 |
[Clinical and bacteriological evaluation of ceftriaxone (CTRX) dosed once daily in children with community-acquired pneumonia].
Topics: Ceftriaxone; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Drug Resistance, Microbial; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Infusions, Intravenous; Male; Pneumonia, Bacterial; Streptococcal Infections; Streptococcus pneumoniae | 1999 |
Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime.
Topics: Adult; Anti-Bacterial Agents; Cefuroxime; Cephalosporins; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Pneumonia, Bacterial | 1999 |
[Efficacy and safety of cefozopran (CZOP) monotherapy and combination therapy with CZOP and amikacin (AMK) for infections accompanying hematological diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cefozopran; Cephalosporins; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Immunocompromised Host; Male; Middle Aged; Pneumonia, Bacterial; Sepsis | 2000 |
An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Cefuroxime; Cephalosporins; Drug Costs; Evaluation Studies as Topic; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies | 2000 |
Intermittent and continuous ceftazidime infusion for critically ill trauma patients.
Topics: Adolescent; Adult; Aged; Ceftazidime; Cephalosporins; Chi-Square Distribution; Critical Illness; Cross Infection; Drug Administration Schedule; Female; Follow-Up Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Probability; Treatment Outcome; Wounds and Injuries | 2000 |
Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactam Resistance; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillin G; Penicillins; Pneumonia, Bacterial; Streptococcus pneumoniae | 2001 |
Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies | 2001 |
Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
Topics: Aged; Amikacin; Ceftazidime; Cephalosporins; Critical Care; Cross Infection; Drug Therapy, Combination; Female; Hospital Mortality; Hospitals, Teaching; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Spain; Survival Analysis; Treatment Outcome | 2001 |
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.
Topics: Adult; Aged; Ceftazidime; Cephalosporins; Critical Care; Cross Infection; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Safety; Tobramycin | 2001 |
Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial.
Topics: Adult; Cefepime; Cefotaxime; Cephalosporins; Empiricism; Female; HIV Infections; Humans; Male; Pneumonia, Bacterial; Treatment Outcome | 2001 |
A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Erythromycin; Female; Fluoroquinolones; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2001 |
Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cross Infection; Cytokines; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Interleukin-1; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Sepsis; Statistics, Nonparametric; Thienamycins; Tumor Necrosis Factor-alpha | 2002 |
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Tolerance; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2002 |
[Importance of a cefpirome-vancomycin combination on bactericidal kinetics in severe MRSA infections in intensive care].
Topics: Adult; Aged; Bacteremia; Cefpirome; Cephalosporins; Critical Care; Drug Therapy, Combination; Female; Humans; Male; Methicillin Resistance; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin | 2002 |
140 other study(ies) available for cephalosporin c and Pneumonia, Bacterial
| Article | Year |
|---|---|
Use of antibiotics and factors associated with treatment failure among 152,245 patients with pneumonia treated in the community - a retrospective cohort study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Fluoroquinolones; Humans; Israel; Male; Middle Aged; Penicillins; Pneumonia, Bacterial; Retrospective Studies; Treatment Failure | 2022 |
Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Cefepime; Cephalosporins; Cyclooctanes; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Lung; Mice; Microbial Sensitivity Tests; Neutropenia; Piperidines; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Specific Pathogen-Free Organisms | 2020 |
Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Cephalosporins; Cross Infection; DNA, Bacterial; Humans; Italy; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Pneumonia, Bacterial; Prevalence; Public Health Surveillance; Staphylococcal Infections; Staphylococcus aureus; Virulence; Whole Genome Sequencing | 2019 |
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Tazobactam; United States | 2020 |
Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010-2018.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Female; Fluoroquinolones; Guideline Adherence; Hospitalization; Humans; Japan; Length of Stay; Male; Middle Aged; Penicillins; Pneumonia, Bacterial; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Severity of Illness Index; Societies, Medical; Time Factors | 2020 |
Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthcare-Associated Pneumonia; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm?
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Comorbidity; Emergency Service, Hospital; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Severity of Illness Index | 2021 |
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Chlamydial Pneumonia; Chlamydophila pneumoniae; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Legionella pneumophila; Macrolides; Male; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gene Expression; Hospitalization; Humans; Isoenzymes; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tazobactam; United States | 2018 |
Cefquinome-loaded microsphere formulations against Klebsiella pneumonia infection during experimental infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Cephalosporins; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Host-Pathogen Interactions; Inflammation Mediators; Interleukin-1beta; Interleukin-8; Klebsiella Infections; Klebsiella pneumoniae; Lung; Male; Microspheres; Particle Size; Pneumonia, Bacterial; Polyesters; Rats, Wistar; Surface Properties; Technology, Pharmaceutical; Time Factors; Tumor Necrosis Factor-alpha | 2018 |
Ceftolozane-tazobactam for the treatment of multidrug-resistant
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis; Tazobactam; Treatment Outcome | 2018 |
Are third-generation cephalosporins associated with a better prognosis than amoxicillin-clavulanate in patients hospitalized in the medical ward for community-onset pneumonia?
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Pneumonia, Bacterial; Retrospective Studies | 2018 |
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bone Diseases, Infectious; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2019 |
Treatment of community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Female; Gentamicins; Guideline Adherence; Haemophilus Infections; Haemophilus influenzae; Humans; Length of Stay; Male; Middle Aged; Norway; Penicillins; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Practice Guidelines as Topic; Severity of Illness Index; Streptococcus pneumoniae; Time Factors | 2018 |
Cefquinome-Loaded Microsphere Formulations in Protection against Pneumonia with Klebsiella pneumonia Infection and Inflammatory Response in Rats.
Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cephalosporins; Cytokines; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Delivery Systems; Inflammation; Injections, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Male; Microspheres; Pneumonia, Bacterial; Polylactic Acid-Polyglycolic Acid Copolymer; Rats, Wistar | 2019 |
Introduction.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Pseudomonas; Staphylococcal Infections; Staphylococcus aureus | 2019 |
Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cross Infection; Drug Dosage Calculations; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Pneumonia, Bacterial | 2013 |
Ceftaroline - a cause for neutropenia.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Neutropenia; Pneumonia, Bacterial | 2013 |
Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Cephalosporins; Drug Resistance, Bacterial; Feces; Klebsiella Infections; Klebsiella pneumoniae; Male; Pneumonia, Bacterial; Rats | 2014 |
Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Skin Diseases, Bacterial | 2014 |
The lack of specificity of tracheal aspirates in the diagnosis of pulmonary infection in intubated children.
Topics: Anti-Bacterial Agents; Catheters; Cefepime; Cephalosporins; Child, Preschool; Colony Count, Microbial; Female; Humans; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Intubation, Intratracheal; Male; Neutrophils; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Prospective Studies; Respiration, Artificial; Time Factors; Trachea | 2014 |
Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cohort Studies; Community-Acquired Infections; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae; Young Adult | 2014 |
[Ceftaroline fosamil in community-acquired and nosocomial pneumonia].
Topics: Animals; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Pneumonia, Staphylococcal; Streptococcus pneumoniae | 2014 |
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pneumonia, Bacterial; Tazobactam; United States | 2014 |
In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Topics: Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Ceftazidime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Female; Humans; Imipenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Treatment Outcome | 2014 |
Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Drug Utilization; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Skin Diseases, Bacterial | 2014 |
Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Basidiomycota; Cephalosporins; Cohort Studies; Community-Acquired Infections; Critical Care; Drug Therapy, Combination; Female; Fluoroquinolones; Guidelines as Topic; Humans; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2015 |
[Zinforo™ (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].
Topics: Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Staphylococcal Infections | 2014 |
Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Creatinine; Female; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Plasma; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome | 2015 |
Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Europe; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Monte Carlo Method; Pneumonia, Bacterial; Skin Diseases, Bacterial; Treatment Outcome | 2015 |
Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Registries; Retrospective Studies; Skin Diseases, Bacterial | 2016 |
High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Drug Utilization; Emergency Service, Hospital; Female; Fluoroquinolones; France; Humans; Male; Penicillins; Pneumonia, Bacterial; Prohibitins; Retrospective Studies; Treatment Outcome | 2015 |
Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Critical Care; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pilot Projects; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2015 |
Ceftobiprole medocaril (Mabelio). Just another injectable cephalosporin.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Cephalosporins; Humans; Pneumonia, Bacterial | 2015 |
Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study.
Topics: Aged; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cefepime; Cephalosporins; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Female; Germany; Hospital Mortality; Hospitals, University; Humans; Kaplan-Meier Estimate; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Proteus Infections; Proteus mirabilis; Retrospective Studies; Serratia Infections; Serratia marcescens | 2016 |
Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Clinical Trials as Topic; Community-Acquired Infections; Computer Simulation; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Models, Biological; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae | 2017 |
Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gentamicins; Humans; Longitudinal Studies; Microbial Sensitivity Tests; Minocycline; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Tigecycline; Vietnam | 2016 |
Cardiac Arrest in Pediatric Patients Receiving Azithromycin.
Topics: Azithromycin; Cardiopulmonary Resuscitation; Cephalosporins; Cohort Studies; Community-Acquired Infections; Databases, Factual; Female; Heart Arrest; Hospital Mortality; Humans; Male; Multivariate Analysis; Penicillins; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2017 |
Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Salvage Therapy; Shock, Septic; Survival Analysis; Tazobactam | 2017 |
First case of pneumonia caused by Cupriavidus pauculus in an infant in the Gulf Cooperation Council.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Cupriavidus; Gram-Negative Bacterial Infections; Humans; Infant; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Saudi Arabia | 2017 |
Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Macrolides; Male; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome | 2008 |
Should we change antibiotic prophylaxis for lung surgery? Postoperative pneumonia is the critical issue.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Bronchitis; Case-Control Studies; Cefamandole; Cephalosporins; Dose-Response Relationship, Drug; Drug Administration Schedule; Education, Medical, Continuing; Female; Follow-Up Studies; France; Humans; Incidence; Lung Diseases; Male; Middle Aged; Multivariate Analysis; Pneumonectomy; Pneumonia, Bacterial; Postoperative Complications; Preoperative Care; Probability; Prospective Studies; Reference Values; Risk Assessment; Surgical Wound Infection; Survival Rate | 2008 |
[High mortality. Elderly pneumonia patients need aggressive therapy].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cephalosporins; Comorbidity; Fluoroquinolones; Humans; Pneumonia, Bacterial; Risk Factors | 2008 |
Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial | 2009 |
[Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Drug Costs; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2009 |
[Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?].
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Ertapenem; Humans; Ofloxacin; Pneumonia, Bacterial | 2010 |
Fixed-dose combination of cefepime plus amikacin (potentox) inhibits pneumonia infection.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Antioxidants; Catalase; Cefepime; Cephalosporins; Drug Therapy, Combination; Klebsiella Infections; Klebsiella pneumoniae; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Pneumonia, Bacterial; Rats; Rats, Wistar; Superoxide Dismutase | 2009 |
Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model.
Topics: Acinetobacter baumannii; Amikacin; Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Lung; Mice; Ofloxacin; Pneumonia, Bacterial; Polymerase Chain Reaction; Pseudomonas aeruginosa; Random Allocation; Survival Analysis | 2010 |
Ceftaroline fosamil: drug profile and clinical data.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rabbits; Skin Diseases, Bacterial | 2011 |
Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Infusions, Intravenous; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcal Infections | 2011 |
Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Community-Acquired Infections; Europe; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; United States | 2011 |
Changing needs of community-acquired bacterial pneumonia: experience with ceftaroline fosamil. Preface.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Prescription of antibiotics for adults hospitalized with community-acquired pneumonia in Korea in 2004: a population-based descriptive study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Clindamycin; Community-Acquired Infections; Drug Prescriptions; Drug Therapy, Combination; Female; Fluoroquinolones; Guideline Adherence; Hospitalization; Humans; International Classification of Diseases; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Practice Guidelines as Topic; Republic of Korea | 2012 |
Ceftaroline (Teflaro): a new cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcal Infections | 2011 |
Animal model methodology: immunocompetent or leucopenic rats, which is the best? Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cefepime; Cephalosporinase; Cephalosporins; Cyclophosphamide; Drug Therapy, Combination; Enterobacter cloacae; Immunocompromised Host; Injections, Intraperitoneal; Leukopenia; Male; Models, Animal; Pneumonia, Bacterial; Rats; Rats, Wistar | 2012 |
Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.
Topics: Acute Disease; Animals; Anti-Infective Agents; Ceftazidime; Cephalosporins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Inflammation; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2013 |
An overlooked cause of impaired consciousness in a hemodialysis patient.
Topics: Aged; Anti-Bacterial Agents; Anticonvulsants; Cefepime; Cephalosporins; Consciousness Disorders; Diabetic Nephropathies; Electroencephalography; Female; Humans; Pneumonia, Bacterial; Renal Dialysis; Status Epilepticus; Treatment Outcome; Uremia | 2012 |
An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit?
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Approval; Humans; Minocycline; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Tigecycline; United States | 2012 |
[Bacterial pneumonia in HIV-infected patients (excluding mycobacterial infection)].
Topics: Actinomycetales Infections; AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Cephalosporins; Community-Acquired Infections; Evidence-Based Medicine; France; Haemophilus influenzae; HIV Infections; Humans; Immunocompromised Host; Influenza Vaccines; Nocardia Infections; Pneumococcal Vaccines; Pneumonia, Bacterial; Rhodococcus equi; Severity of Illness Index; Streptococcus pneumoniae; Treatment Outcome | 2012 |
Citrobacter koseri pneumonia and meningitis in an infant.
Topics: Anti-Bacterial Agents; Cefotaxime; Cephalosporins; Citrobacter koseri; Enterobacteriaceae Infections; Gentamicins; Humans; Infant, Newborn; Lung Abscess; Male; Meningitis, Bacterial; Pneumonia, Bacterial | 2002 |
Determination of the frequency of inadequate antibiotic therapy using calculation of indication failure (IF), cumulative indication failure (CIF), and balanced indication failure (BIF).
Topics: Anti-Bacterial Agents; Bacterial Infections; Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Drug Resistance, Multiple; Empiricism; Enterobacteriaceae Infections; Humans; Imipenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Treatment Failure | 2003 |
[Efficacy and safety of cefditoren pivoxil in treatment of respiratory infections, a clinical study].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Pneumonia, Bacterial; Product Surveillance, Postmarketing; Respiratory Tract Infections; Streptococcus pneumoniae | 2003 |
Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats.
Topics: Administration, Inhalation; Animals; Antibodies; Bronchoalveolar Lavage Fluid; Cefotiam; Cephalosporins; Escherichia coli; Escherichia coli Infections; Injections, Intraperitoneal; Interleukin-6; Intubation, Intratracheal; Leukocyte Count; Lymphocyte Count; Male; Neutrophils; Oxygen; Oxygen Consumption; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Rats; Rats, Wistar; Sepsis; Staphylococcus aureus; Survival Analysis; Tumor Necrosis Factor-alpha | 2003 |
Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia.
Topics: Aged; Bronchoalveolar Lavage; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Cross Infection; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitals, University; Humans; Infusions, Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Prospective Studies; Respiratory Mucosa | 2003 |
Antibiotic tissue concentrations revisited in lungs.
Topics: Cefepime; Cephalosporins; Humans; Infusions, Intravenous; Lung; Pneumonia, Bacterial | 2003 |
[Pharmacokinetics of antibiotics in inflamed and healthy lung tissue].
Topics: Anti-Bacterial Agents; Cefpirome; Cephalosporins; Empyema, Pleural; Extracellular Space; Humans; Lung; Microbial Sensitivity Tests; Microdialysis; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Tazobactam; Thoracotomy | 2003 |
Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
Topics: Alkylating Agents; Animals; Ceftazidime; Cephalosporins; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Combinations; Female; Granulocyte Colony-Stimulating Factor; Mice; Neutropenia; Pneumonia, Bacterial; Pseudomonas Infections; Survival Analysis | 2004 |
In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.
Topics: Animals; Butyrates; Ceftaroline; Cephalosporins; Disease Models, Animal; Enterococcus; Male; Methicillin Resistance; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Microbial Sensitivity Tests; Oxazoles; Pneumonia, Bacterial; Staphylococcal Infections; Staphylococcus | 2004 |
Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Colony Count, Microbial; Guinea Pigs; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Porins; Thienamycins; Treatment Outcome | 2005 |
Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteriological Techniques; Bronchoalveolar Lavage Fluid; Cephalosporins; Cross Infection; Early Diagnosis; Female; France; Humans; Imipenem; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Pneumonia, Bacterial; Population Surveillance; Practice Guidelines as Topic; Prospective Studies; Pseudomonas Infections; Treatment Outcome; Ventilators, Mechanical | 2005 |
Continuous infusion beta-lactams for intensive care unit pulmonary infections.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Intensive Care Units; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; United States | 2005 |
Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Disease Models, Animal; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Pneumonia, Bacterial; Porins; Treatment Outcome | 2005 |
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Thienamycins | 2005 |
Pneumonia and pleuritis in a mare.
Topics: Animals; Anti-Infective Agents; Blood Cell Count; Blood Chemical Analysis; Blood Gas Analysis; Cephalosporins; Female; Horse Diseases; Horses; Metronidazole; Pleurisy; Pneumonia, Bacterial; Streptococcal Infections; Streptococcus equi; Treatment Outcome | 2006 |
Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Enterobacter cloacae; Female; Haemophilus influenzae; Immunocompetence; Klebsiella pneumoniae; Mice; Models, Animal; Pneumonia, Bacterial; Statistics, Nonparametric; Tissue Distribution | 2006 |
Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Colony Count, Microbial; Imipenem; In Vitro Techniques; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Plasmids; Pneumonia, Bacterial; Porins; Rats; Rats, Wistar; Thienamycins; Treatment Outcome | 2006 |
Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bronchopneumonia; Cephalosporins; Cross Infection; Electrophoresis, Capillary; Female; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Intubation, Intratracheal; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Sputum; Treatment Outcome | 2006 |
Antibiotic treatment of community acquired pneumonia varies widely across Germany.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Germany; Humans; Macrolides; Male; Middle Aged; Multivariate Analysis; Pneumonia, Bacterial; Practice Patterns, Physicians'; Treatment Outcome | 2007 |
[Efficacies of ceftazidime and cefepime in rats with experimental pneumonia caused by extended-spectrum beta-lactamase-producing strain of Klebsiella pneumonia].
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Female; Klebsiella Infections; Klebsiella pneumoniae; Pneumonia, Bacterial; Rats; Rats, Sprague-Dawley | 2006 |
The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Resistance, Multiple; Empiricism; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospitals, Teaching; Humans; Intensive Care Units; Male; Middle Aged; Missouri; Penicillins; Pneumonia, Bacterial; Prospective Studies; Survival Rate; Urinary Tract Infections; Ventilators, Mechanical | 2006 |
Postoperative pneumonia after major pulmonary resections: an unsolved problem in thoracic surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Cefazolin; Cephalosporins; Enterobacteriaceae; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonectomy; Pneumonia, Bacterial; Postoperative Complications | 2007 |
Antibiotic use in nursing home-acquired pneumonia.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Cefepime; Ceftriaxone; Cephalosporins; Cross Infection; Drug Therapy, Combination; Drug Utilization; Homes for the Aged; Hospital Mortality; Hospitalization; Humans; Injections, Intramuscular; Nursing Homes; Pneumonia, Aspiration; Pneumonia, Bacterial; Survival Rate; Treatment Failure | 2007 |
[Current features of antibacterial therapy of nosocomial pneumonia].
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pneumonia, Bacterial; Siberia; Survival Rate; Treatment Outcome | 2008 |
Bacterial and fungal pneumonias after lung transplantation.
Topics: Anti-Bacterial Agents; Antiviral Agents; Candidiasis; Cefepime; Cephalosporins; Cytomegalovirus Infections; Humans; Lung Transplantation; Mycoses; Patient Selection; Pneumonia; Pneumonia, Bacterial; Retrospective Studies | 2008 |
Drug-resistant Streptococcus pneumoniae.
Topics: beta-Lactam Resistance; Ceftazidime; Cephalosporins; Community-Acquired Infections; Pneumococcal Infections; Pneumonia, Bacterial; Streptococcus pneumoniae | 1996 |
Treatment of aspiration or tracheostomy-associated pneumonia in neurologically impaired children: effect of antimicrobials effective against anaerobic bacteria.
Topics: Adolescent; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Ceftazidime; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Clavulanic Acid; Clavulanic Acids; Clindamycin; Female; Fever; Humans; Male; Penicillins; Pneumonia, Aspiration; Pneumonia, Bacterial; Retrospective Studies; Seizures; Ticarcillin; Tracheostomy; Unconsciousness | 1996 |
[Treatment of bacterial pneumonias with cefuroxime-axetil. Predictive value of measurement of the in vitro susceptibility].
Topics: Adolescent; Adult; Aged; Cefuroxime; Cephalosporins; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Predictive Value of Tests; Prospective Studies; Streptococcus pneumoniae | 1996 |
Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefotaxime; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Drug Combinations; Drug Therapy, Combination; Female; Klebsiella Infections; Klebsiella pneumoniae; Lung; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia, Bacterial; Tazobactam; Ticarcillin | 1996 |
Prospective study of epidemiology and prognostic factors in community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Chlamydophila pneumoniae; Community-Acquired Infections; Drug Resistance, Microbial; Erythromycin; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Mycoplasma pneumoniae; Penicillin Resistance; Pneumonia, Bacterial; Prognosis; Prospective Studies; Streptococcus pneumoniae | 1996 |
Agrobacterium radiobacter pneumonia in a patient with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Ceftriaxone; Cephalosporins; Female; Gentamicins; Gram-Negative Bacterial Infections; HIV Infections; Humans; Microbial Sensitivity Tests; Netilmicin; Pneumonia, Bacterial; Rhizobium; Stavudine | 1996 |
Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cefepime; Cefotaxime; Cephalosporins; Drug Resistance, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Kidney; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rats; Rats, Wistar | 1997 |
Severe community-acquired pneumonia caused by atypical organisms.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cefuroxime; Cephalosporins; Clarithromycin; Clavulanic Acids; Community-Acquired Infections; Critical Care; Diagnosis, Differential; Drug Therapy, Combination; Erythromycin; Female; Gentamicins; Humans; Male; Middle Aged; Netilmicin; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Psittacosis; Radiography; Treatment Failure | 1997 |
Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cefuroxime; Cephalosporins; Clavulanic Acids; Community-Acquired Infections; Drug Therapy, Combination; Humans; Pneumonia, Bacterial | 1997 |
Relapsing infection due to Enterobacter species: lessons of heterogeneity.
Topics: Abscess; Bacteremia; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cefotaxime; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Drug Resistance, Microbial; Enterobacter; Enterobacteriaceae Infections; Humans; Mutation; Pneumonia, Bacterial | 1997 |
Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Ciprofloxacin; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Respiration, Artificial | 1997 |
Salmonella infection and pneumonia in a patient with kyphoscoliosis.
Topics: Adult; Ceftriaxone; Cephalosporins; Humans; Intellectual Disability; Kyphosis; Male; Pneumonia, Bacterial; Salmonella Infections; Scoliosis | 1996 |
[Ceftriaxone (Rocefin) in the treatment of bronchopulmonary infections].
Topics: Bacteria; Bronchitis; Ceftriaxone; Cephalosporins; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Sputum; Time Factors | 1997 |
Pancoast's syndrome due to chronic pneumonia by Pasteurella multocida.
Topics: Adult; Cefuroxime; Cephalosporins; Chronic Disease; Diagnosis, Differential; Humans; Male; Pancoast Syndrome; Pasteurella Infections; Pasteurella multocida; Pneumonia, Bacterial; Radiography | 1997 |
Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa.
Topics: Bacterial Proteins; Bronchi; Cephalosporins; Cohort Studies; Critical Care; DNA, Bacterial; Environmental Microbiology; Female; Follow-Up Studies; Forecasting; Humans; Incidence; Length of Stay; Lung; Lung Diseases, Obstructive; Male; Middle Aged; Multivariate Analysis; Patient Admission; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment; Risk Factors; Sputum; Ventilators, Mechanical | 1998 |
The choice of antibacterial drugs.
Topics: Administration, Oral; Anti-Bacterial Agents; Cefotaxime; Ceftazidime; Cephalosporins; Community-Acquired Infections; Costs and Cost Analysis; Cross Infection; Drug Resistance, Microbial; Drug Resistance, Multiple; Enterococcus; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Macrolides; Meningitis, Bacterial; Meningitis, Meningococcal; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Neutropenia; Pneumococcal Infections; Pneumonia, Bacterial; Systemic Inflammatory Response Syndrome; Urinary Tract Infections | 1998 |
Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome.
Topics: Aged; Bacteremia; Ceftazidime; Cephalosporins; Female; Humans; Imipenem; Male; Middle Aged; Neoplasms; Neutropenia; Pneumonia, Bacterial; Thienamycins; Treatment Outcome | 1998 |
Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Colony Count, Microbial; Creatinine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enterobacter cloacae; Enterobacteriaceae Infections; Lung; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rats; Rats, Mutant Strains; Time Factors; Treatment Outcome | 1998 |
Community acquired pneumonia in elderly people. Current British guidelines need revision.
Topics: Aged; Cephalosporins; Community-Acquired Infections; Drug Resistance, Microbial; Hospitalization; Humans; Pneumonia, Bacterial; Practice Guidelines as Topic | 1998 |
[Studies on penetration of cefepime into respiratory tract using broncho-alveolar lavage and sputum].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cefepime; Cephalosporins; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Respiratory System; Sputum | 1997 |
Meropenem monotherapy as empiric treatment of nosocomial lower respiratory tract infection.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Critical Illness; Cross Infection; Drug Therapy, Combination; Humans; Meropenem; Pneumonia, Bacterial; Severity of Illness Index; Thienamycins; Tobramycin; Treatment Outcome | 1998 |
Should third-generation cephalosporins be the empirical treatment of choice for severe community-acquired pneumonia in adults?
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Australia; Cephalosporins; Child; Community-Acquired Infections; Drug Utilization; Humans; Pneumonia, Bacterial; Treatment Outcome | 1998 |
[Management of community-acquired pneumopathies of adults in the city and at the hospital].
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Hospitalization; Humans; Penicillin G; Penicillin Resistance; Penicillins; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Radiography, Thoracic | 1998 |
Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients.
Topics: Adult; Cefotaxime; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cost-Benefit Analysis; Humans; Pneumonia, Bacterial; Treatment Outcome | 1998 |
Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients.
Topics: Adult; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cost-Benefit Analysis; Humans; Pneumonia, Bacterial; Treatment Outcome | 1998 |
Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.
Topics: Bacteremia; Cefepime; Cephalosporins; Evaluation Studies as Topic; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 1998 |
[Pulmonic plague].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Child, Preschool; Diagnosis, Differential; Fluoroquinolones; Humans; Infant; Plague; Pneumonia, Bacterial; Streptomycin | 1998 |
The effects of erythromycin on the electrocardiogram.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefuroxime; Cephalosporins; Electrocardiography; Erythromycin; Female; Heart Rate; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies | 1999 |
Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients.
Topics: Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Case-Control Studies; Ceftazidime; Cephalosporins; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; Female; Hand Disinfection; Humans; Intensive Care Units; Intubation, Intratracheal; Male; Middle Aged; Pneumonia, Bacterial; Respiration, Artificial; Retrospective Studies; Risk Factors | 1999 |
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imipenem; Lung; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar | 1999 |
[Bacteriological and clinical break points: evaluation of the usefulness of cefozopran based on MIC].
Topics: Cefozopran; Cephalosporins; Citrobacter; Enterobacter; Enterococcus; Escherichia coli; Humans; Klebsiella; Methicillin Resistance; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Serratia; Staphylococcus aureus | 1999 |
Moraxella catarrhalis pneumonia and bacteremia in an otherwise healthy child.
Topics: Bacteremia; Ceftriaxone; Cephalosporins; Female; Humans; Infant; Moraxella catarrhalis; Pneumonia, Bacterial | 1999 |
Nosocomial pneumonia with isolation of anaerobic bacteria in ICU patients: therapeutic considerations and outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria, Anaerobic; Cefotaxime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Prevotella; Retrospective Studies; Treatment Outcome | 1999 |
The best treatment for pneumonia: new clues, but no definitive answers.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Clinical Trials as Topic; Drug Therapy, Combination; Fluoroquinolones; Humans; Length of Stay; Macrolides; Pneumonia, Bacterial; Risk; Severity of Illness Index | 1999 |
Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Ceftazidime; Cephalosporins; Colony Count, Microbial; Drug Therapy, Combination; Humans; Mice; Pneumonia, Bacterial; Pseudomonas Infections; Survival Analysis; Time Factors; Urinary Tract Infections | 1999 |
[Cefotaxime in sequential therapy of community acquired pneumonia].
Topics: Adult; Bacterial Infections; Cefotaxime; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial | 1999 |
In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2000 |
[Bacteremia and Pasteurella multocida pneumonia revealing HIV infection].
Topics: Adult; Amoxicillin; Animals; Anti-Infective Agents; Bacteremia; Bites and Stings; Cats; Cefotaxime; Cephalosporins; HIV Infections; HIV Seropositivity; Humans; Male; Pasteurella Infections; Pasteurella multocida; Pefloxacin; Penicillins; Pneumonia, Bacterial; Time Factors | 1999 |
Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Drug Resistance, Microbial; Enterobacter cloacae; Enterobacteriaceae Infections; Half-Life; Imipenem; Kidney Diseases; Male; Meropenem; Penicillinase; Pneumonia, Bacterial; Protein Binding; Rats; Rats, Wistar; Thienamycins; Uranyl Nitrate | 2000 |
Cefoperazone induced gastrointestinal haemorrhage.
Topics: Aged; Cefoperazone; Cellulitis; Cephalosporins; Female; Gastrointestinal Hemorrhage; Humans; Injections, Intravenous; Male; Pneumonia, Bacterial | 1999 |
Pasteurella multocida: a case report of bacteremic pneumonia and 10-year laboratory review.
Topics: Aged; Animals; Ceftriaxone; Cephalosporins; Ciprofloxacin; Dogs; Humans; Male; Pasteurella Infections; Pasteurella multocida; Pneumonia, Bacterial; Zoonoses | 2000 |
Antimicrobial therapy for ambulatory pediatrics.
Topics: Ambulatory Care; Anti-Bacterial Agents; Anti-Infective Agents; Cefixime; Cefuroxime; Cephalexin; Cephalosporins; Child; Fluoroquinolones; Humans; Macrolides; Otitis Media; Penicillins; Pharyngitis; Pneumonia, Bacterial; Sinusitis; Urinary Tract Infections | 1999 |
[Bacteremia caused by Enterobacter cloacae: emergence of antibiotic resistance after antibiotic prophylaxis].
Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Aortic Aneurysm, Abdominal; Bacteremia; Cefamandole; Cephalosporin Resistance; Cephalosporins; Drug Resistance, Multiple; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Male; Pneumonia, Bacterial; Postoperative Complications | 2000 |
[The influence of severe infections on the natural killer cells in neonates with vary gestational age].
Topics: Antibodies, Monoclonal; Antigens, CD; Cephalosporins; Female; Humans; Infant, Newborn; Killer Cells, Natural; Male; Meningitis, Bacterial; Pneumonia, Bacterial; Sepsis; Severity of Illness Index; Treatment Outcome | 2000 |
Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase.
Topics: Animals; Bacterial Proteins; beta-Lactamases; Biofilms; Ceftazidime; Cephalosporins; Chromosomes, Bacterial; Chronic Disease; Drug Resistance, Microbial; Electrophoresis, Gel, Pulsed-Field; Female; Isoelectric Focusing; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pregnancy; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Lew; Time Factors | 2000 |
Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Enterococcus; Erythromycin; Female; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Risk Factors; Vancomycin Resistance | 2000 |
[Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract].
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Bronchitis; Cefuroxime; Cephalosporins; Chronic Disease; Community-Acquired Infections; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Inpatients; Penicillins; Pneumonia, Bacterial; Respiratory Tract Infections; Streptococcus pneumoniae | 2000 |
Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia.
Topics: Adult; Aged; Cefepime; Ceftazidime; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial | 2001 |
[Studies on the biological and clinical characteristics of acquired pneumonia caused by K. planticola].
Topics: Adult; Aged; Aged, 80 and over; Cephalosporins; Female; Humans; Klebsiella; Klebsiella Infections; Male; Middle Aged; Pneumonia, Bacterial | 1998 |
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Topics: Ceftazidime; Cephalosporins; Critical Care; Cross Infection; Drug Incompatibility; Drug Stability; Drug Therapy, Combination; Humans; Infusions, Intravenous; Midazolam; Nicardipine; Pneumonia, Bacterial; Propofol; Temperature; Vancomycin | 2001 |
Clinical analysis of community-acquired pneumonia in the elderly.
Topics: Aged; Aged, 80 and over; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Pneumonia, Bacterial; Pneumonia, Viral; Prognosis; Prospective Studies | 2001 |
Relation of antibiotic use to risk of myocardial infarction in the general population.
Topics: Anti-Bacterial Agents; Cephalosporins; Chlamydophila Infections; Chlamydophila pneumoniae; Databases, Factual; Female; Humans; Insurance; Macrolides; Male; Medical Records; Middle Aged; Myocardial Infarction; Penicillins; Pneumonia, Bacterial; Proportional Hazards Models; Quinolones; Retrospective Studies; Risk Factors; Tetracyclines; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2002 |
Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Cefozopran; Cephalosporins; Cilastatin; Ciprofloxacin; Disease Models, Animal; Imipenem; Infusions, Parenteral; Male; Mice; Pneumonia, Bacterial; Protease Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Respiration, Artificial; Thienamycins | 2001 |
Rapid detection of Haemophilus influenzae type b in Bangladeshi children with pneumonia and meningitis by PCR and analysis of antimicrobial resistance.
Topics: Bangladesh; Ceftriaxone; Cephalosporins; Child, Preschool; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Haemophilus Infections; Haemophilus influenzae type b; Humans; Infant; Male; Meningitis, Haemophilus; Pneumonia, Bacterial; Polymerase Chain Reaction; Reproducibility of Results; Sensitivity and Specificity | 2001 |
Emergence of new pathogens in CF: the devil we know or the devil we don't know?
Topics: Antibiotic Prophylaxis; Cephalexin; Cephalosporins; Cystic Fibrosis; Humans; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Pseudomonas Infections | 2002 |
Eradication of endotracheal tube biofilm by nebulised gentamicin.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biofilms; Cefotaxime; Cefuroxime; Cephalosporins; Cross Infection; Female; Gentamicins; Humans; Infusions, Parenteral; Intubation, Intratracheal; Male; Middle Aged; Pneumonia, Bacterial; Statistics, Nonparametric | 2002 |